Niemann-Pick disease: a drug reduces the risk of death by 55% in certain children

Niemann-Pick disease: a drug reduces the risk of death by 55% in certain children
For families dealing with Niemann-Pick disease, every year counts. A drug has just reached a major milestone: it has shown a significant reduction in the risk of death in patients with this rare genetic disease.

On November 17, 2026, the FDA approved Lembaz (adrabetadex), the first treatment to demonstrate a survival benefit in certain early forms of the disease. The results are based on 36 patients and need to be interpreted with caution.

A rare disease that can strike in the first years of life

Niemann-Pick disease type C, often abbreviated NPC, is a progressive lysosomal disease: cells have difficulty managing certain lipids, which accumulate little by little. It is linked to genetic anomalies most often affecting the NPC1 gene, more rarely NPC2. Transmission is autosomal recessive: both parents generally carry a genetic anomaly without being sick, and the child can be affected if he inherits the two altered copies.

Manifestations vary greatly depending on age. In infants, the disease can be revealed by an increase in the volume of the liver and spleen, cholestatic jaundice or pulmonary damage. In childhood, neurological signs often take over: developmental delay, hypotonia, clumsiness evolving into ataxia, speech or swallowing disorders, epileptic seizures, abnormal movements, cataplexy triggered by laughter, or even vertical supranuclear palsy of gaze or saccades.

These signs are not specific, which can lengthen the journey before confirmation. The diagnosis is based on a combination of clinical and biological arguments, with genetic confirmation by the identification of biallelic pathogenic variants of NPC1 or NPC2. This complexity ties in with the broader difficulties of diagnosing rare diseases, where wandering can weigh heavily on families.

In this context, the American announcement represents an important step forward.

A 55% reduction in the risk of death with this treatment

On November 17, 2026, the FDA approved Lembaz (adrabetadex), developed by Mandos, a subsidiary of Beren Therapeutics. To evaluate its effectiveness, the American agency relied on 36 patients treated in three clinical studies and an expanded access program. Their survival was compared to that of an external control group composed of patients with similar characteristics.

The results show an important difference:

  • 8.5 years median survival in treated patients;
  • 4.9 years in the control group;
  • 55% reduction in risk of death associated with the treatment.

This benefit was seen whether or not patients were taking miglustat, another medication used in some NPC situations.

However, a methodological reservation remains: this was not a classic randomized trial with random allocation between treatment and placebo. Unmeasured differences between groups cannot therefore be completely excluded.

A treatment that requires close hearing monitoring

Lembaz’s endorsement does not mean his administration is simple. Lembaz is administered every two weeks by intrathecal injection, directly into the spinal canal, by a healthcare professional.

But its use carries a significant risk: hearing damage which may be permanent. The FDA therefore requires a hearing assessment before treatment, then regular assessments during its administration. Dose adjustment may be necessary.

Other reported side effects include fatigue, vomiting, back pain, headache, fever, diarrhea and balance problems.

For families, progress is therefore real, but it is accompanied by a specialized care pathway and regular monitoring.

A hope, but no access yet in France

The American authorization concerns adults and children weighing at least 7 kg, whose neurological symptoms began before 6 years of age. It therefore does not apply to all people with the disease.

No European or French authorization has been announced to date.

This decision is nevertheless the result of nearly twenty years of research. The National Institutes of Health (NIH) particularly recall the importance of studies on the natural evolution of the disease, initiated in 2006, to measure the benefits of a treatment. For ultra-rare childhood diseases, this knowledge is essential. It makes it possible to better identify the first signs, to reduce diagnostic wandering as much as possible and, above all, to avoid wasting precious time.

Lembaz does not cure Niemann-Pick disease. But demonstrating that a treatment can prolong survival in such a serious disease represents a major shift. For the families concerned, it is a new perspective: that of finally having a therapeutic option capable of modifying, at least in part, the course of the disease.